Kodiak Sciences

Scientist / Senior Scientist, Protein Engineering

Kodiak Sciences  •  Palo Alto, CA (Onsite)  •  20 days ago
Apply
AI can make mistakes so check important info. Chat history is never stored.
51
AI Success™

Job Description

Kodiak Sciences Inc. is a fast-growing, clinical-stage biopharmaceutical company focused on transforming ophthalmology through innovative therapeutics. Our Antibody Biopolymer Conjugate Drug (ABCD) platform integrates protein and peptide engineering & discovery, polymer chemistry, small molecule drug discovery, bioconjugation, and drug delivery technologies to address high-prevalence ophthalmic diseases.  We are seeking a talented Scientist/Senior Scientist to advance peptide therapeutic drug discovery and development programs with a strong emphasis on molecular design, organic synthesis, and analytical characterization.  Key Responsibilities 
  • Lead the design, synthesis, and optimization of peptide-based therapeutics, integrating Structure-Activity Relationship (SAR) considerations, developability and conjugation strategies to drive candidate progression. 
  • Perform hands-on experimental work including, but not limited to DNA-Encoded Library synthesis, Macrocyclic and Linear Peptide synthesis, polymer conjugation chemistry, purification and analytical evaluation, data interpretation and developability risk assessment.  
  • Develop and apply analytical and biophysical methods (e.g., LC-MS, HPLC, NMR, SEC, DLS) to characterize peptides and bioconjugates, including purity, heterogeneity, stability, and aggregation. 
  • Collaborate cross-functionally and communicate scientific findings through presentations, reports, and regulatory documentation. 
Education / Qualifications 
  • Ph.D. in Medicinal Chemistry, Organic Chemistry, Chemical Biology, Biochemistry, or a related field, with either (i) 0–3 years of relevant postdoctoral experience and at least one first-author publication in a high-impact, peer-reviewed journal (preferred), or (ii) 3+ years of relevant industry experience.
  • Experience working with either of the following methodologies, such as Solid Phase Peptide Synthesis (SPPS), DNA-Encoded Library (DEL) synthesis, liquid phase parallel synthesis and/or polymer-based bioconjugates is highly desirable.
  • Strong experience in therapeutic development of peptides, and/or conjugated biologics, experience in analytical characterization is a plus. 
  • Proficiency in chromatographic and mass spectrometry-based techniques, with an understanding of developability attributes such as stability, solubility, and manufacturability is a plus. 
  • Experience in using software such as PyMol, MOE, Schrödinger, Maestro, DataWarrior, Vortex is a plus.
  • Experience with CD and/or FTIR for peptide secondary structure determination is a plus.
  • Hands-on experience with biochemical assays, including SPR, ELISA, fluorescence-based assays, is a plus. 
  • Demonstrated ability to independently drive scientific work in a collaborative, cross-functional environment, with strong problem-solving and communication skills. 
Kodiak Sciences

About Kodiak Sciences

Kodiak is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead investigational medicine, tarcocimab, is a novel anti-VEGF antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases. KSI-501 is our second investigational medicine, a first-in-class anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate designed to inhibit both IL-6 mediated inflammation and VEGF-mediated angiogenesis and vascular permeability. KSI-501 is being developed for the treatment of high prevalence retinal vascular diseases to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. KSI-101, our third product candidate, is a novel anti-IL-6, VEGF-trap bispecific protein for the treatment of retinal inflammatory diseases. We are advancing our platform technology to embed small molecules and other active pharmaceutical ingredients for multifactorial diseases.

WORKING AT KODIAK

We foster a culture of curiosity, creativity, compassion and courage. Our collective goal is to make a difference in the world. We do that as a team driven by the shared desire to tackle some of the world’s biggest challenges. If this sounds exciting, we want to hear from you!

Kodiak supports a vibrant and active lifestyle, striving to provide an optimal work-life balance. We are located in Palo Alto, in the heart of the world-class biotech hub of Silicon Valley, and within walking distance to California Avenue’s shops, restaurants and public transportation.

Industry
Biotech & Life Sciences
Company Size
51-200 employees
Headquarters
Palo Alto, California
Year Founded
2009
Social Media